Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Thyroid Neoplasms 2Paraganglioma, Extra-Adrenal 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Cancer Metastatic 1Pheochromocytoma 1Multiple Endocrine Neoplasia Type 1 1Differentiated Thyroid Cancer (DTC) 1Differentiated Thyroid Cancer 1Carcinoma, Neuroendocrine 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adrenocortical Carcinoma 1

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × lenvatinib × Endocrine × Clear all
NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Mayo Clinic

Phase 2 Completed
3 enrolled 9 charts
CNSEndocrine

Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡